Brokers Issue Forecasts for PROF Q1 Earnings

Profound Medical Corp. (NASDAQ:PROF) – Investment analysts at Raymond James issued their Q1 2026 EPS estimates for shares of Profound Medical in a report issued on Tuesday, February 18th. Raymond James analyst M. Freeman anticipates that the company will earn ($0.24) per share for the quarter. Raymond James currently has a “Strong-Buy” rating on the stock. The consensus estimate for Profound Medical’s current full-year earnings is ($1.15) per share. Raymond James also issued estimates for Profound Medical’s Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.19) EPS and Q4 2026 earnings at ($0.14) EPS.

Profound Medical Trading Up 4.3 %

Shares of PROF stock opened at $7.08 on Wednesday. Profound Medical has a 1-year low of $5.63 and a 1-year high of $11.42. The firm’s 50-day simple moving average is $7.01 and its 200-day simple moving average is $7.76. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.12 and a quick ratio of 5.16. The firm has a market cap of $212.68 million, a P/E ratio of -5.28 and a beta of 0.88.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Stonepine Capital Management LLC purchased a new position in Profound Medical in the fourth quarter valued at approximately $1,502,000. Maven Securities LTD purchased a new position in Profound Medical in the fourth quarter valued at approximately $376,000. Letko Brosseau & Associates Inc. raised its holdings in Profound Medical by 1.0% in the fourth quarter. Letko Brosseau & Associates Inc. now owns 1,211,150 shares of the company’s stock valued at $8,689,000 after buying an additional 12,375 shares during the period. Bleichroeder LP raised its holdings in Profound Medical by 37.5% in the fourth quarter. Bleichroeder LP now owns 183,333 shares of the company’s stock valued at $1,377,000 after buying an additional 50,000 shares during the period. Finally, Alyeska Investment Group L.P. purchased a new position in Profound Medical in the fourth quarter valued at approximately $1,202,000. Hedge funds and other institutional investors own 47.86% of the company’s stock.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.